Bayer investigational colorectal cancer drug meets primary endpoint
Regorafenib is an oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases (TK) used for the treatment of metastatic colorectal cancer (mCRC). The double-blind, international, multicenter,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.